Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

Merck (MRK) announced the initiation of pivotal phase III studies on four of its cancer candidates, most of which it added to its pipeline from the acquisitions and collaboration deals made in 2022. Patients are now actively enrolling in these studies.The first candidate is an LSD1 inhibitor, bomedemstat, for which a study called MK-3543-006 has begun for the treatment of certain patients with essential thrombocythemia (ET). Separately, multiple phase II studies are ongoing, which are evaluating bomedemstat ...